Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
19.00
-0.40 (-2.06%)
At close: Mar 13, 2026
Market Cap71.14B +7.9%
Revenue (ttm)43.22B -5.0%
Net Income3.59B +55.3%
EPS1.35 +57.6%
Shares Outn/a
PE Ratio19.83
Forward PEn/a
Dividend0.35 (1.76%)
Ex-Dividend DateJul 24, 2025
Volume1,621,767
Average Volume2,171,519
Open19.33
Previous Close19.40
Day's Range19.00 - 19.33
52-Week Range12.78 - 29.00
Beta0.69
RSI40.71
Earnings DateMar 24, 2026

About HKG:2196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory... [Read more]

Sector Healthcare
Founded 1994
Employees 40,557
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2196
Full Company Profile

Financial Performance

In 2024, HKG:2196's revenue was 41.07 billion, a decrease of -0.80% compared to the previous year's 41.40 billion. Earnings were 2.77 billion, an increase of 16.13%.

Financial numbers in CNY Financial Statements

News

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

2 years ago - Reuters

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment

3 years ago - Forbes

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

4 years ago - CNBC International TV

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

5 years ago - CNBC